A Randomized, Double-blinded and Placebo-controlled Multicenter Phase? Clinical Trial to Evaluate the Efficacy and Safety of Qingfeng Ganke Granules in the Treatment of Postinfectious Cough(Wind-evil Loving Lung Syndrome)

Qingfeng Ganke Granules in the Treatment of Postinfectious Cough(Wind-evil Loving Lung Syndrome): a Randomized, Double-blinded and Placebo-controlled Multicenter Phase? Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002297

Enrollment

Unknown

Registered

2012-06-19

Start date

2011-04-02

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postinfectious Cough

Interventions

high-dose group:Qingfeng Ganke granule 2 bags(12g) Bid

low-dose group:Qingfeng Ganke granule 1 bag(6g) Bid and Qingfeng

placebo:Qingfeng Ganke granule 1 bag(6g) Bid and Qingfeng

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients meet the diagnosis standard of postinfectious cough; 2. The TCM classification is wind-evil loving lung syndrome; 3. Scoring of cough during day and/or night>=2; 4. Cough duration is from 3-8 weeks; 5. Aged 18 to 65 years old; 6. Patients voluntarily signed the informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with a serious primary cardio-cerebrovascular, lung, liver, kidney, or hematological disease, or other serious diseases affected the survival, such as cancer or AIDS; 2. ALT or AST> 1.5 times of upper limit, abnormal serum creatitine, white blood cell count10*10^9/L, and/or N>80%; 3. Body temperature higher than 37.3 degree C; 4. Patients who use drugs to treat postinfectious cough in last one month; 5. Pregnant or lactating women, or women who have birth plan; 6. Allergic constitution or be allergy to the drug composition used in the trial; 7. mental illness; 8. patients who is participating or participated in last 3 months in other drug clinical trials.

Design outcomes

Primary

Measure	Time frame
Duration for cough to disappear;Duration for cough to relieve;	—

Secondary

Measure	Time frame
Disappearance rate of cough symptoms and degree;Recovery rate of cough symptoms and degree;the TCM symptoms;cough-specific quality of life questionnaire;	—

Countries

China

Contacts

Public ContactMao Bing

West China Hospital, Sichuan University

maobing@medmail.com.cn+86 18980601724

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026